| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Camille Locht | Q61756452 |
| P2093 | author name string | Stéphane Cauchi | |
| P2860 | cites work | Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract | Q24523604 |
| Bordetella filamentous hemagglutinin plays a critical role in immunomodulation, suggesting a mechanism for host specificity | Q24535631 | ||
| Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET | Q81298678 | ||
| Improving access to vaccines through tiered pricing | Q87456777 | ||
| The pertussis hypothesis: Bordetella pertussis colonization in the etiology of asthma and diseases of allergic sensitization | Q91470583 | ||
| Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 | ||
| Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway | Q28214681 | ||
| Anti-immunology: evasion of the host immune system by bacterial and viral pathogens | Q28298920 | ||
| Live pertussis vaccines: will they protect against carriage and spread of pertussis? | Q30235094 | ||
| Bordetella adenylate cyclase toxin interacts with filamentous haemagglutinin to inhibit biofilm formation in vitro | Q30275500 | ||
| Cyclic AMP-mediated suppression of neutrophil extracellular trap formation and apoptosis by the Bordetella pertussis adenylate cyclase toxin | Q30303150 | ||
| Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm | Q30388854 | ||
| Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation | Q30423650 | ||
| Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus | Q30431134 | ||
| Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. | Q30449654 | ||
| Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough | Q30819553 | ||
| Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice | Q30873716 | ||
| Estimating the duration of pertussis immunity using epidemiological signatures | Q33513972 | ||
| T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis | Q33564283 | ||
| Role of the microbiota in immunity and inflammation | Q33752553 | ||
| Extracellular adenosine-mediated modulation of regulatory T cells | Q33878542 | ||
| Acellular pertussis vaccines | Q33889544 | ||
| Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. | Q34000735 | ||
| Vaccines: science, health, longevity, and wealth | Q34120026 | ||
| IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice | Q34185860 | ||
| Development of a pertussis component vaccine in Japan | Q34247807 | ||
| Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age | Q34346137 | ||
| Bordetella pertussis pathogenesis: current and future challenges | Q34383541 | ||
| Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma | Q34499739 | ||
| Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. | Q34530115 | ||
| G(i/o) protein-dependent and -independent actions of Pertussis Toxin (PTX). | Q34633613 | ||
| A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. | Q34738678 | ||
| Adenylate cyclase toxin subverts phagocyte function by RhoA inhibition and unproductive ruffling | Q34844344 | ||
| Bordetella adenylate cyclase toxin differentially modulates toll-like receptor-stimulated activation, migration and T cell stimulatory capacity of dendritic cells. | Q35217146 | ||
| Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines | Q35548872 | ||
| Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. | Q35765491 | ||
| Can innate immunity be enhanced to treat microbial infections? | Q35777677 | ||
| Contribution of pertussis toxin to the pathogenesis of pertussis disease | Q36226458 | ||
| Bordetella adenylate cyclase toxin: a swift saboteur of host defense | Q36365962 | ||
| Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussi | Q36369855 | ||
| Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection | Q36396894 | ||
| Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin | Q36525295 | ||
| Bordetella pertussis: new concepts in pathogenesis and treatment | Q36839952 | ||
| Bordetella pertussis adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions | Q37015041 | ||
| Coughing precipitated by Bordetella pertussis infection | Q37638384 | ||
| Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host | Q37678929 | ||
| Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism | Q37698331 | ||
| Th17 cells and Tregs: unlikely allies | Q37700178 | ||
| The virulence factors of Bordetella pertussis: talented modulators of host immune response. | Q38129761 | ||
| The Yin-Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation | Q38185741 | ||
| A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals | Q38234491 | ||
| Epigenetic control of myeloid cell differentiation, identity and function. | Q38298238 | ||
| Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. | Q38323912 | ||
| Trained immunity: A program of innate immune memory in health and disease. | Q38814347 | ||
| Bordetella pertussis virulence factors affect phagocytosis by human neutrophils | Q39514867 | ||
| First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin | Q39814748 | ||
| Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection | Q40202103 | ||
| BCG and protection against inflammatory and auto-immune diseases | Q40203403 | ||
| Heterologous vaccine effects | Q40696555 | ||
| Unconventional, adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine | Q41151708 | ||
| A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers | Q41860045 | ||
| Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule. | Q41864177 | ||
| Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models. | Q42511534 | ||
| Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. | Q43781170 | ||
| Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. | Q44036620 | ||
| Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children | Q44733749 | ||
| Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells | Q46653871 | ||
| Bordetella pertussis adenylate cyclase toxin disrupts functional integrity of bronchial epithelial layers. | Q47691335 | ||
| Will we have new pertussis vaccines? | Q47698503 | ||
| Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response | Q51015773 | ||
| Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor. | Q52646111 | ||
| Evidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6-35 Months in Guinea-Bissau: A Time for Reflection? | Q53278311 | ||
| Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. | Q54417363 | ||
| Bordetella pertussis filamentous hemagglutinin itself does not trigger anti-inflammatory interleukin-10 production by human dendritic cells | Q60364394 | ||
| Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice | Q61766626 | ||
| Bordetella pertussis Infection in 2-Month-Old Infants Promotes Type 1 T Cell Responses | Q61766641 | ||
| Cough production, leucocytosis and serology of rats infected intrabronchially with Bordetella pertussis | Q72256793 | ||
| Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis | Q72405781 | ||
| IL-4 promotes airway eosinophilia by suppressing IFN-gamma production: defining a novel role for IFN-gamma in the regulation of allergic airway inflammation | Q73401131 | ||
| Modulation of the infant immune responses by the first pertussis vaccine administrations | Q79372116 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Bordetella pertussis | Q137103 |
| respiratory tract infection | Q754447 | ||
| contact dermatitis | Q783903 | ||
| respiratory syncytial virus | Q1052913 | ||
| attenuated vaccine | Q1810913 | ||
| pertussis vaccine | Q7170955 | ||
| heterologous immunity | Q71229317 | ||
| P304 | page(s) | 2872 | |
| P577 | publication date | 2018-01-01 | |
| 2018-12-07 | |||
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases | |
| P478 | volume | 9 |
Search more.